Pfizer's stock fell 2.09% over the past month and has dropped nearly 23% since its one-year high in July 2024. The company reported Q1 earnings exceeding EPS expectations but falling short on revenues. Despite stable year-end results, especially from COVID and non-COVID products, Pfizer's stock has disappointed investors, evidenced by a nearly 60% decline since its December 2021 high. Looking ahead, Pfizer forecasts FY 2025 revenues between $61 billion and $64 billion, aiming for growth in oncology sales with several drugs in late-stage development.
Pfizer's stocks have struggled in 2025, down 23% from their yearly high, despite exceeding EPS expectations but falling short in revenue due to COVID product sales decline.
Despite strong Q1 earnings results, Pfizer has seen stock prices drop nearly 60% since their all-time high in December 2021, reflecting investor concerns.
Collection
[
|
...
]